High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · Oct 7, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special type of fat called medium-chain triglycerides (MCTs) on infants with a condition known as biliary atresia. Biliary atresia is a serious liver condition that affects how the liver and bile ducts work, and it often requires a surgery called the Kasai procedure before the baby is 3 months old. The goal of the study is to see if providing nutritional support with MCTs can help improve the health and nutrition of these infants.

To be eligible for this trial, infants must have undergone the Kasai procedure and be under 3 months old. However, babies with severe liver problems, like cirrhosis or other serious health conditions, cannot participate. If your child is eligible and takes part in this study, they will be monitored closely to see how well they respond to the nutritional support provided. This trial is still looking for participants, and it could provide important insights into better nutritional care for infants with biliary atresia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The Kasai procedure for infants with biliary atresia under the age of 3 months.
• Exclusion Criteria:
• • Complicated with cirrhosis, hepatitis, or other hepatic disorders;
• • Complicated with other systemic serious diseases (such as congenital multiple malformations, chromosome abnormalities)